10 Stocks Under $20 That Will Explode
According to a June 9, 2026, Reuters report, world markets have swung sharply over the past week, reflecting heightened uncertainty about the economic outlook.
Adma Biologics Inc. (ADMA)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Rubric Capital Management David Rosen | 9,339,414 | $78,170,895 | +417% | 0.72% |
| 2. | Caligan Partners David Johnson | 5,725,007 | $47,918,309 | +21% | 2.25% |
| 3. | D E Shaw D. E. Shaw | 5,274,597 | $44,148,376 | +841% | 0.02% |
| 4. | Nantahala Capital Management Wilmot B. Harkey And Daniel Mack | 2,359,993 | $19,753,141 | 0.65% | |
| 5. | Ranger Investment Management Conrad Doenges (Cio) | 2,115,417 | $17,706,040 | -8% | 1.12% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $7.91 | 6,400 | $50,624.00 | 520,284 | 2026-05-27 | Filing | |
| $8.01 | 12,500 | $100,125.00 | 513,884 | 2026-05-12 | Filing | |
| $8.01 | 12,500 | $100,125.00 | 501,384 | 2026-05-11 | Filing | |
| $15.39 | 7,000 | $107,730.00 | 2,045,730 | 2026-03-06 | Filing | |
| $15.67 | 7,000 | $109,690.00 | 2,038,730 | 2026-03-05 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $15.16 | 6,000 | $90,960.00 | 2,112,777 | 2026-03-16 | Filing | |
| $15.16 | 15,000 | $227,400.00 | 2,118,777 | 2026-03-16 | Filing | |
| $15.63 | 10,096 | $157,800.48 | 466,600 | 2026-03-09 | Filing | |
| $16.08 | 6,000 | $96,480.00 | 2,284,379 | 2026-02-17 | Filing | |
| $16.08 | 15,000 | $241,200.00 | 2,290,379 | 2026-02-17 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 38,355,684 | $321,037,075 | 0% | |
| 2. | 17,116,022 | $143,261,104 | 0% | |
| 3. | 10,103,809 | $84,568,881 | 0% | |
| 4. | 10,088,490 | $84,440,661 | 0% | |
| 5. | 8,756,374 | $73,290,850 | 0.01% |
News See All
10 Best Cheap Stocks Under $10 to Buy in June
On May 27, Kathleen Entwistle, Morgan Stanley Private Wealth Management Managing Director & Private Wealth Advisor, joined 'Fast Money' on CNBC to talk about buying opportunities in the current market...
10 Best Russell 2000 Stocks to Invest In According to Hedge Funds
On May 29, Reuters reported that the Russell 2000 fell 0.6%, lagging the broader Wall Street indexes, which closed at new highs.
Here's What Analysts Think About ADMA Biologics (ADMA)
ADMA Biologics, Inc. (NASDAQ:ADMA) is one of the best small cap stocks to buy for 10x potential. On May 7, Mizuho lowered the price target on ADMA Biologics, Inc.
Canaccord Cuts PT on ADMA Biologics Inc. (ADMA) But Remains a Buy on Shares
ADMA Biologics Inc. (NASDAQ:ADMA) is one of the best healthcare stocks to buy for the long term. Canaccord cut the price target on ADMA Biologics Inc.
15 Best Small Cap Stocks to Buy for 10x Potential
On May 11, Dan Niles, Niles Investment Management founder, appeared on CNBC’s ‘The Exchange’ to talk about his view on equity markets while conducting a comparison with the prior periods.
10 Best Healthcare Stocks to Buy for the Long Term
On May 7, Haig Bathgate, CEO of Callanish Capital, appeared on CNCB to talk about his bullish view on the global markets amid the Iran war, and how its impact would be short-lived, especially when compared...
ADMA Biologics, Inc. (NASDAQ:ADMA) Q1 2026 Earnings Call Transcript
Operator: Good afternoon, and welcome to the ADMA Biologics First Quarter 2026 Financial Results and Business Update Conference Call on Wednesday, May 6, 2026.
ADMA Biologics, Inc. (ADMA) Initiated at Buy as Canaccord Cites Improving Revenue and Margin Trends
TheFly reported on April 21 that Canaccord Genuity initiated coverage of ADMA with a Buy rating and set a price target of $21.
Top 10 AI-Powered Biotech Stocks to Buy Right Now
Franklin Equity reported on February 16 that, following a protracted period of uncertainty in the previous year, the biotechnology sector has entered 2026 on a firmer and more stable foundation.
Hedge Fund Resource Center